Montelukast Accord (Montelukast Sodium)

Montelukast Sodium, the active ingredient in Montelukast Accord, is a leukotriene receptor antagonist presented as a tablet for oral use. It is indicated for long‑term control of asthma, relief of seasonal and perennial allergic rhinitis, and as a preventive measure for exercise‑induced bronchoconstriction in both adult and pediatric patients.

GNH USA supplies Montelukast Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU regulatory standards and is manufactured under GMP conditions for consistent quality.

Montelukast Accord, a leukotriene receptor antagonist, is used to treat conditions mediated by cysteinyl leukotrienes.

- Asthma maintenance therapy: improves long‑term control and reduces exacerbations. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching. - Prevention of exercise‑induced bronchoconstriction: reduces airway narrowing during physical activity.

Montelukast may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Headache - Abdominal pain or dyspepsia - Cough - Nasopharyngitis - Fatigue - Diarrhoea

Serious or Rare Side Effects: - Neuropsychiatric events such as agitation, depression or suicidal thoughts - Severe allergic reactions including angioedema, urticaria or anaphylaxis - Hepatic enzyme elevations or hepatitis - Eosinophilic granulomatosis with polyangiitis (Churg‑Strauss syndrome) - Stevens‑Johnson syndrome or toxic epidermal necrolysis

Before prescribing Montelukast, clinicians should consider several safety aspects.

- Assess asthma control before initiating therapy: ensure the patient is on appropriate inhaled controller medication. - Monitor for neuropsychiatric symptoms: report any mood changes, depression or suicidal thoughts promptly. - Use with caution in patients with hepatic impairment: consider dose adjustment or close monitoring. - Avoid in individuals with known hypersensitivity to montelukast or any excipient. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Montelukast can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Phenobarbital, rifampin, carbamazepine: strong enzyme inducers that may lower montelukast plasma levels. - Erythromycin, ketoconazole: potent CYP3A4 inhibitors that may raise exposure. - Warfarin: possible increase in INR; monitor coagulation parameters.

Moderate Interactions (Monitor Closely): - Theophylline: additive central nervous system effects may occur. - β2‑agonists: no direct pharmacokinetic interaction, but overall asthma control should be assessed. - Live attenuated vaccines: immune response may be altered; consider timing of vaccination.